Pulmonology

Alvar Agustí, MD, previews key 2027 GOLD report changes, from initial COPD treatment and new biologic data to a GOLD Science Committee call to action.

Type 2 biologics reduced mucus plugs in asthma trials, and quantitative imaging may help detect this treatable phenotype, according to a GOLD 2026 session.

CT-detected mucus plugs affect up to 67% of patients with COPD and are linked to worse lung function, exacerbations, and mortality, even without symptoms.

At GOLD 2026, Alvar Agustí, MD, PhD, speaks on COPD underdiagnosis and misdiagnosis, barriers to spirometry in primary care, and managing pre-COPD.

In a 50-patient rhinovirus challenge study, a single nasal ETH47 dose cut peak viral load 40-fold, though the primary endpoint was not significant.

October 2026 pulmonology highlights include FDA accelerated approval of Voceryq for recurrent respiratory papillomatosis and CHEST 2026 data.

HCPLive previews GOLD 2026 in Philadelphia, November 5-6, with sessions on the 2027 GOLD Report, mucus plugging, and exacerbations, plus expert interviews.

In 20 patients with PAH, lower baseline RVEF was linked to greater RV functional recovery and PVR reduction after 24 weeks of sotatercept, per a CHEST 2026 abstract.

Michael Wechsler, MD, discusses SWIFT/AGILE data showing 59% of patients in remission with depemokimab at year 1 maintained it at year 2.

Stay updated with the latest healthcare breakthroughs, including new TRANSCEND-T2D-2 data and FDA actions.

The plasmid DNA immunotherapy Voceryq gained FDA accelerated approval after 27% of RRP-001 patients needed no surgery for 12 months.

Five CHEST 2026 interviews cover nalbuphine ER for IPF cough, tozorakimab in COPD, depemokimab remission, AD109 in OSA, and robotic bronchoscopy.

Jean Elwing, MD, and pulmonologists from across the US discuss how risk, payer coverage, and patient resources shape PAH therapy selection.

In PHINDER, IPF had the highest PVD-B65 mortality risk scores. Rali discusses why PH in ILD is missed and when to refer for right heart catheterization.

Parth Rali, MD, explains how the AHA/ACC A-through-E categories compare with ESC risk tiers and how hospitals can meet the class 1 PERT recommendation.